Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL005 in Acute Myocardial Infarction
NCT05984134Phase 2Completed
- Sponsor
- Northland Biotech
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of thymosin beta-4 in acute myocardial infarction (AMI), sponsored by Northland Biotech. Started Jul 2022; status: completed.
02
Drugs
thymosin beta-4
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT05984134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984134.